The potency of lempuyang wangi (Zingiber zerumbet) as aldose reductase inhibitor: an alternative of anti-diabetes drugs

Abstract

Aldose reductase is an enzyme that plays a role in glucose metabolism. An increase in aldose reductase will trigger an increase in blood sugar concentration by converting glucose to sorbitol. Increased sorbitol conditions will result in diabetes complications such as diabetic cataracts. So we need an inhibitor that can inhibit the working system of the aldose reductase enzyme. One of the medicinal plants that has anti-diabetic properties is lempuyang wangi. Lempuyang wangi has a secondary metabolite compound which has the potential as an antidiabetic. The purpose of this study was to examine the anti-diabetic properties of lempuyang wangi using the in silico method. In this research, docking was carried out with Pymol and Pyrx software, and visualization using Biovia Discovery Studio to see the interaction between zerumbone compounds and aldose reductase and compared with zopolrestat compounds. The docking result of zopolrestat as a comparison compound is -9 kcal/mol, while xanthorrhizol has a binding affinity value of -8,7 kcal/mol and has the same amino acid bonds with zopolrestat, making it a potential candidate as an antidiabetic herbal drug in inhibiting the working system of the aldose reductase enzyme